GSK pens $745M deal for phase 1 drug that hits sweet spots of COPD, oligonucleotides
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides. The drugmaker is paying $85 million upfront to Empirico for the rights…